Illumina stock rallies 7.13% and outperforms competitors
Updated
Updated · MarketWatch · May 1
Illumina stock rallies 7.13% and outperforms competitors
8 articles · Updated · MarketWatch · May 1
Shares closed at $135.78 on Friday, extending gains for a second day as trading volume reached 2.8 million, well above the 50-day average of 1.6 million.
Illumina beat peers including Labcorp, Charles River Laboratories and Quest Diagnostics, all of which fell, during a mixed broader market session with the S&P 500 up and the Dow down.
Despite the jump, the stock remains 12.7% below its 52-week high of $155.53 reached on 22 January.
As low-cost sequencing rivals grow, can Illumina's innovation roadmap protect its commanding 70% market share?
Is Illumina's future in selling more sequencing machines or in monetizing the genomic data they produce?